{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T02:18:55Z","timestamp":1784600335790,"version":"3.55.0"},"reference-count":126,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","pathologyjournal.rcpa.edu.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.pathol.2022.11.004","type":"journal-article","created":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T07:45:56Z","timestamp":1669275956000},"page":"8-18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["The role of HER2 as a therapeutic biomarker in gynaecological malignancy: potential for use beyond uterine serous carcinoma"],"prefix":"10.1016","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4500-6679","authenticated-orcid":false,"given":"Karen L.","family":"Talia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2387-1274","authenticated-orcid":false,"given":"Natalie","family":"Banet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Buza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pathol.2022.11.004_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the Phase II KEYNOTE-158 Study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2022.11.004_bib2","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.pathol.2022.11.004_bib3","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1038\/sj.onc.1210477","article-title":"The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis","volume":"26","author":"Moasser","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.pathol.2022.11.004_bib4","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41571-021-00558-1","article-title":"EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment","volume":"19","author":"Friedlaender","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.pathol.2022.11.004_bib5","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2017-000279","article-title":"Activating HER2 mutations as emerging targets in multiple solid cancers","volume":"2","author":"Connell","year":"2017","journal-title":"ESMO Open"},{"key":"10.1016\/j.pathol.2022.11.004_bib6","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41571-019-0268-3","article-title":"HER2-targeted therapies - a role beyond breast cancer","volume":"17","author":"Oh","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.pathol.2022.11.004_bib7","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/431525b","article-title":"Lung cancer: intragenic ERBB2 kinase mutations in tumours","volume":"431","author":"Stephens","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.pathol.2022.11.004_bib8","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2017-LB-103","article-title":"Abstract LB-103: landscape of somatic ERBB2 mutations: findings from AACR GENIE and comparison to ongoing ERBB2 mutant basket study","volume":"77","author":"Schram","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.pathol.2022.11.004_bib9","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1200\/JCO.2008.19.9844","article-title":"Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review","volume":"28","author":"Dawood","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2022.11.004_bib10","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer","volume":"353","author":"Romond","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pathol.2022.11.004_bib11","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.pathol.2022.11.004_bib12","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1038\/modpathol.2013.113","article-title":"Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice","volume":"26","author":"Buza","year":"2013","journal-title":"Mod Pathol"},{"key":"10.1016\/j.pathol.2022.11.004_bib13","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/d41573-019-00201-w","article-title":"Breast cancer drug approvals by the US FDA from 1949 to 2018","volume":"19","author":"Leo","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.pathol.2022.11.004_bib14","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pathol.2022.11.004_bib15","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1258\/jrsm.2008.070289","article-title":"Media influence on Herceptin subsidization in Australia: application of the rule of rescue?","volume":"101","author":"Mackenzie","year":"2008","journal-title":"J\u00a0R Soc Med"},{"key":"10.1016\/j.pathol.2022.11.004_bib16","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(21)00086-3","article-title":"Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial","volume":"22","author":"Siena","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.pathol.2022.11.004_bib17","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1470-2045(16)00150-9","article-title":"Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12\/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial","volume":"17","author":"Sartore-Bianchi","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.pathol.2022.11.004_bib18","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.ajog.2004.10.605","article-title":"Racial differences in the overexpression of epidermal growth factor type II receptor (HER2\/neu): a major prognostic indicator in uterine serous papillary cancer","volume":"192","author":"Santin","year":"2005","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.pathol.2022.11.004_bib19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2007.09.007","article-title":"An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study","volume":"108","author":"Grushko","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.pathol.2022.11.004_bib20","first-page":"122","article-title":"Comparative immunohistochemical study of endometrioid and serous papillary carcinoma of endometrium","volume":"22","author":"Halperin","year":"2001","journal-title":"Eur J Gynaecol Oncol"},{"key":"10.1016\/j.pathol.2022.11.004_bib21","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ygyno.2009.09.025","article-title":"Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study","volume":"116","author":"Fleming","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.pathol.2022.11.004_bib22","doi-asserted-by":"crossref","first-page":"343","DOI":"10.5858\/arpa.2012-0416-RA","article-title":"HER2\/neu in endometrial cancer: a promising therapeutic target with diagnostic challenges","volume":"138","author":"Buza","year":"2014","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.pathol.2022.11.004_bib23","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1365-2559.2009.03464.x","article-title":"HER-2\/neu receptor gene status in endometrial carcinomas: a tissue microarray study","volume":"56","author":"Xu","year":"2010","journal-title":"Histopathology"},{"key":"10.1016\/j.pathol.2022.11.004_bib24","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ijgo.2008.04.008","article-title":"Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2\/neu","volume":"102","author":"Santin","year":"2008","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.pathol.2022.11.004_bib25","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1136\/ijgc-00009577-200609000-00027","article-title":"HER-2\/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications","volume":"16","author":"Villella","year":"2006","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.pathol.2022.11.004_bib26","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1136\/ijgc-00009577-200605000-00064","article-title":"Use of trastuzumab in the treatment of metastatic endometrial cancer","volume":"16","author":"Jewell","year":"2006","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.pathol.2022.11.004_bib27","first-page":"1271","article-title":"Overexpression of HER-2\/neu in uterine serous papillary cancer","volume":"8","author":"Santin","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pathol.2022.11.004_bib28","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1200\/JCO.2017.76.5966","article-title":"Randomized Phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2\/neu","volume":"36","author":"Fader","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2022.11.004_bib29","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.1158\/1078-0432.CCR-20-0953","article-title":"Randomized Phase II trial of carboplatin-paclitaxel compared with carboplatin-paclitaxel-trastuzumab in advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress Her 2\/Neu (NCT01367002): updated overall survival analysis","volume":"26","author":"Fader","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pathol.2022.11.004_bib30","doi-asserted-by":"crossref","first-page":"687","DOI":"10.5858\/arpa.2020-0207-RA","article-title":"HER2 testing in endometrial serous carcinoma: time for standardized pathology practice to meet the clinical demand","volume":"145","author":"Buza","year":"2021","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.pathol.2022.11.004_bib31","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/PGP.0000000000000711","article-title":"HER2 testing and reporting in endometrial serous carcinoma: practical recommendations for HER2 immunohistochemistry and fluorescent in situ hybridization: proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual Meeting","volume":"40","author":"Buza","year":"2021","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.pathol.2022.11.004_bib32","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1136\/ijgc-2021-002753","article-title":"Uterine serous carcinoma: key advances and novel treatment approaches","volume":"31","author":"Ferriss","year":"2021","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.pathol.2022.11.004_bib33","doi-asserted-by":"crossref","first-page":"170","DOI":"10.6004\/jnccn.2018.0006","article-title":"Uterine neoplasms, version 1.2018, NCCN clinical practice guidelines in Oncology","volume":"16","author":"Koh","year":"2018","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.pathol.2022.11.004_bib34","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.ygyno.2020.10.017","article-title":"Uterine serous carcinoma: molecular features, clinical management, and new and future therapies","volume":"160","author":"Lee","year":"2021","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.pathol.2022.11.004_bib35","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1200\/JCO.2006.09.2775","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer","volume":"25","author":"Wolff","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2022.11.004_bib36","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"31","author":"Wolff","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2022.11.004_bib37","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline focused update","volume":"36","author":"Wolff","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2022.11.004_bib38","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.5858\/arpa.2016-0331-CP","article-title":"HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology","volume":"140","author":"Bartley","year":"2016","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.pathol.2022.11.004_bib39","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1365-2559.2008.03028.x","article-title":"Assessment of a HER2 scoring system for gastric cancer: results from a validation study","volume":"52","author":"Hofmann","year":"2008","journal-title":"Histopathology"},{"key":"10.1016\/j.pathol.2022.11.004_bib40","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1038\/modpathol.2015.98","article-title":"Assessment of a HER2 scoring system for colorectal cancer: results from a validation study","volume":"28","author":"Valtorta","year":"2015","journal-title":"Mod Pathol"},{"key":"10.1016\/j.pathol.2022.11.004_bib41","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/bjc.2017.422","article-title":"HER2 expression patterns in paired primary and metastatic endometrial cancer lesions","volume":"118","author":"Halle","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.pathol.2022.11.004_bib42","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/s41379-021-00997-2","article-title":"Histopathologic features and molecular genetic landscape of HER2-amplified endometrial carcinomas","volume":"35","author":"Ross","year":"2022","journal-title":"Mod Pathol"},{"key":"10.1016\/j.pathol.2022.11.004_bib43","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/gcc.22113","article-title":"Marked heterogeneity of HER2\/NEU gene amplification in endometrial serous carcinoma","volume":"52","author":"Buza","year":"2013","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.pathol.2022.11.004_bib44","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ygyno.2020.07.016","article-title":"Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: a multi-institutional cohort study","volume":"159","author":"Erickson","year":"2020","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.pathol.2022.11.004_bib45","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/PGP.0000000000000690","article-title":"Does specimen type have an impact on HER2 status in endometrial serous carcinoma? Discordant HER2 status of paired endometrial biopsy and hysterectomy specimens in the presence of frequent intratumoral heterogeneity","volume":"40","author":"Rottmann","year":"2021","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.pathol.2022.11.004_bib46","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41379-019-0358-x","article-title":"HER2 testing of gynecologic carcinosarcomas: tumor stratification for potential targeted therapy","volume":"33","author":"Rottmann","year":"2020","journal-title":"Mod Pathol"},{"key":"10.1016\/j.pathol.2022.11.004_bib47","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1038\/s41379-021-00746-5","article-title":"Reproducibility of scoring criteria for HER2 immunohistochemistry in endometrial serous carcinoma: a multi-institutional interobserver agreement study","volume":"34","author":"Buza","year":"2021","journal-title":"Mod Pathol"},{"key":"10.1016\/j.pathol.2022.11.004_bib48","article-title":"Characteristics of HER2 gene amplification by fluorescence in situ hybridization in endometrial serous carcinoma","volume":"146","author":"Buza","year":"2022","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.pathol.2022.11.004_bib49","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1200\/JCO.2004.11.154","article-title":"Her-2\/neu overexpression and amplification in uterine papillary serous carcinoma","volume":"22","author":"Slomovitz","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2022.11.004_bib50","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/00004347-199904000-00007","article-title":"HER-2\/neu amplification and overexpression in endometrial carcinoma","volume":"18","author":"Rolitsky","year":"1999","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.pathol.2022.11.004_bib51","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1111\/j.1349-7006.2012.02240.x","article-title":"Clinicopathological and prognostic impact of human epidermal growth factor receptor type 2 (HER2) and hormone receptor expression in uterine papillary serous carcinoma","volume":"103","author":"Togami","year":"2012","journal-title":"Cancer Sci"},{"key":"10.1016\/j.pathol.2022.11.004_bib52","first-page":"5693","article-title":"Amplification and overexpression of HER-2\/neu (c-erbB2) in endometrial cancers: correlation with overall survival","volume":"55","author":"Saffari","year":"1995","journal-title":"Cancer Res"},{"key":"10.1016\/j.pathol.2022.11.004_bib53","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ygyno.2005.08.017","article-title":"Clinical significance of Her-2\/neu overexpression in uterine serous carcinoma","volume":"100","author":"D\u00edaz-Montes","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.pathol.2022.11.004_bib54","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1097\/PAS.0000000000000182","article-title":"HER2 immunohistochemistry significantly overestimates HER2 amplification in uterine papillary serous carcinomas","volume":"38","author":"Mentrikoski","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.pathol.2022.11.004_bib55","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/ajcp\/aqz010","article-title":"Pathologic features and clinical implications of breast cancer with HER2 intratumoral genetic heterogeneity","volume":"152","author":"Muller","year":"2019","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.pathol.2022.11.004_bib56","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.12998\/wjcc.v7.i15.1964","article-title":"HER2 heterogeneity is a poor prognosticator for HER2-positive gastric cancer","volume":"7","author":"Kaito","year":"2019","journal-title":"World J Clin Cases"},{"key":"10.1016\/j.pathol.2022.11.004_bib57","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1200\/JCO.19.02318","article-title":"Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: results from a Phase Ib study","volume":"38","author":"Modi","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2022.11.004_bib58","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S1470-2045(19)30328-6","article-title":"Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study","volume":"20","author":"Banerji","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.pathol.2022.11.004_bib59","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41523-022-00434-w","article-title":"HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment","volume":"8","author":"Miglietta","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.pathol.2022.11.004_bib60","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1524-4741.2007.00396.x","article-title":"Intratumoral heterogeneity of HER2\/neu in breast cancer--a rare event","volume":"13","author":"Hanna","year":"2007","journal-title":"Breast J"},{"key":"10.1016\/j.pathol.2022.11.004_bib61","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jamcollsurg.2012.09.007","article-title":"Does breast tumor heterogeneity necessitate further immunohistochemical staining on surgical specimens?","volume":"216","author":"Greer","year":"2013","journal-title":"J\u00a0Am Coll Surg"},{"key":"10.1016\/j.pathol.2022.11.004_bib62","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/PAI.0b013e31821c821c","article-title":"HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment","volume":"20","author":"Kunz","year":"2012","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.pathol.2022.11.004_bib63","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1097\/PAS.0000000000001682","article-title":"HER-2 amplification in uterine serous carcinoma and serous endometrial intraepithelial carcinoma","volume":"45","author":"Banet","year":"2021","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.pathol.2022.11.004_bib64","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1093\/ajcp\/aqy166","article-title":"Impact of specimen type and specimen number on HER2 status in gastroesophageal junction and gastric adenocarcinoma","volume":"151","author":"Huber","year":"2019","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.pathol.2022.11.004_bib65","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ygyno.2005.03.041","article-title":"Determination of HER2\/neu status in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry and fluorescence in situ hybridization","volume":"98","author":"Santin","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.pathol.2022.11.004_bib66","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1200\/JCO.2001.19.2.354","article-title":"HER-2\/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization","volume":"19","author":"Lebeau","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2022.11.004_bib67","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41379-020-00695-5","article-title":"Detection of ERBB2 amplification in uterine serous carcinoma by next-generation sequencing: an approach highly concordant with standard assays","volume":"34","author":"Robinson","year":"2021","journal-title":"Mod Pathol"},{"key":"10.1016\/j.pathol.2022.11.004_bib68","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ygyno.2015.01.533","article-title":"HER2 over-expressing high grade endometrial cancer expresses high levels of p95HER2 variant","volume":"137","author":"Growdon","year":"2015","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.pathol.2022.11.004_bib69","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ygyno.2017.02.002","article-title":"Objective, domain-specific HER2 measurement in uterine and ovarian serous carcinomas and its clinical significance","volume":"145","author":"Carvajal-Hausdorf","year":"2017","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.pathol.2022.11.004_bib70","doi-asserted-by":"crossref","first-page":"E44","DOI":"10.3390\/cancers13010044","article-title":"HER2 status in high-risk endometrial cancers (PORTEC-3): relationship with histotype, molecular classification, and clinical outcomes","volume":"13","author":"Vermij","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.pathol.2022.11.004_bib71","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/PAS.0000000000001870","article-title":"HER2 overexpression and amplification in uterine carcinosarcomas with serous morphology","volume":"46","author":"Jenkins","year":"2022","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.pathol.2022.11.004_bib72","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1007\/s00428-021-03017-5","article-title":"Histopathological features of HER2 overexpression in uterine carcinosarcoma: proposal for requirements in HER2 testing for targeted therapy","volume":"478","author":"Yoshida","year":"2021","journal-title":"Virchows Arch"},{"key":"10.1016\/j.pathol.2022.11.004_bib73","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1136\/ijgc-2019-000920","article-title":"Molecular variations in uterine carcinosarcomas identify therapeutic opportunities","volume":"30","author":"Crane","year":"2020","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.pathol.2022.11.004_bib74","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ygyno.2006.11.001","article-title":"Uterine carcinosarcoma: immunohistochemical studies on tissue microarrays with focus on potential therapeutic targets","volume":"105","author":"Cimbaluk","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.pathol.2022.11.004_bib75","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ygyno.2005.07.124","article-title":"EGFR expression and HER2\/neu overexpression\/amplification in endometrial carcinosarcoma","volume":"100","author":"Livasy","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.pathol.2022.11.004_bib76","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1097\/PAS.0b013e31825dd4b3","article-title":"The diagnosis of endometrial carcinomas with clear cells by gynecologic pathologists: an assessment of interobserver variability and associated morphologic features","volume":"36","author":"Fadare","year":"2012","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.pathol.2022.11.004_bib77","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/path.4947","article-title":"The genetic landscape of endometrial clear cell carcinomas","volume":"243","author":"DeLair","year":"2017","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.pathol.2022.11.004_bib78","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1002\/cncr.30745","article-title":"Somatic mutation profiles of clear cell endometrial tumors revealed by whole exome and targeted gene sequencing","volume":"123","author":"Le Gallo","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.pathol.2022.11.004_bib79","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/PGP.0000000000000783","article-title":"HER2 expression in endometrial cancers diagnosed as clear cell carcinoma","volume":"41","author":"Cagaanan","year":"2022","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.pathol.2022.11.004_bib80","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13000-016-0553-8","article-title":"Systematic assessment of HER2\/neu in gynecologic neoplasms, an institutional experience","volume":"11","author":"Woo","year":"2016","journal-title":"Diagn Pathol"},{"key":"10.1016\/j.pathol.2022.11.004_bib81","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/PGP.0000000000000248","article-title":"Undifferentiated carcinoma of the endometrium: an expanded immunohistochemical analysis including PAX-8 and basal-like carcinoma surrogate markers","volume":"35","author":"Ramalingam","year":"2016","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.pathol.2022.11.004_bib82","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.3390\/diagnostics11112042","article-title":"Mesonephric-like adenocarcinoma of the uterine corpus: comprehensive immunohistochemical analyses using markers for mesonephric, endometrioid and serous tumors","volume":"11","author":"Kim","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.pathol.2022.11.004_bib83","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1097\/PAS.0b013e31827f576a","article-title":"Poor interobserver reproducibility in the diagnosis of high-grade endometrial carcinoma","volume":"37","author":"Gilks","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.pathol.2022.11.004_bib84","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1245\/s10434-011-1572-z","article-title":"Identification of the coexisting HER2 gene amplification and novel mutations in the HER2 protein-overexpressed mucinous epithelial ovarian cancer","volume":"18","author":"Lin","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.pathol.2022.11.004_bib85","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1097\/PAS.0000000000000268","article-title":"Assessing the HER2 status in mucinous epithelial ovarian cancer on the basis of the 2013 ASCO\/CAP guideline update","volume":"38","author":"Chao","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.pathol.2022.11.004_bib86","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1186\/1471-2407-9-433","article-title":"HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy","volume":"9","author":"McAlpine","year":"2009","journal-title":"BMC Cancer"},{"key":"10.1016\/j.pathol.2022.11.004_bib87","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/PGP.0000000000000302","article-title":"Pattern of HER-2 gene amplification and protein expression in benign, borderline, and malignant ovarian serous and mucinous neoplasms","volume":"36","author":"Mohammed","year":"2017","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.pathol.2022.11.004_bib88","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.1038\/s41467-019-11862-x","article-title":"The molecular origin and taxonomy of mucinous ovarian carcinoma","volume":"10","author":"Cheasley","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.pathol.2022.11.004_bib89","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/JCO.2003.10.104","article-title":"Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group","volume":"21","author":"Bookman","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2022.11.004_bib90","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/PGP.0000000000000812","article-title":"HER2 protein overexpression and gene amplification in tubo-ovarian high-grade serous carcinomas","volume":"41","author":"Ersoy","year":"2022","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.pathol.2022.11.004_bib91","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ygyno.2014.09.003","article-title":"Targeting HER2 in ovarian and uterine cancers: challenges and future directions","volume":"135","author":"Teplinsky","year":"2014","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.pathol.2022.11.004_bib92","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ygyno.2017.07.009","article-title":"Superior in\u00a0vitro and in\u00a0vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2\/neu expression","volume":"147","author":"Menderes","year":"2017","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.pathol.2022.11.004_bib93","doi-asserted-by":"crossref","first-page":"5836","DOI":"10.1158\/1078-0432.CCR-16-2862","article-title":"SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2\/Neu expression","volume":"23","author":"Menderes","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pathol.2022.11.004_bib94","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ygyno.2015.08.002","article-title":"Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in\u00a0vitro and in\u00a0vivo","volume":"139","author":"Schwab","year":"2015","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.pathol.2022.11.004_bib95","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/PGP.0b013e31823bb24d","article-title":"HER2\/neu as a potential target for immunotherapy in gynecologic carcinosarcomas","volume":"31","author":"Guzzo","year":"2012","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.pathol.2022.11.004_bib96","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0191972","article-title":"The prognostic value of HER2 in ovarian cancer: a meta-analysis of observational studies","volume":"13","author":"Luo","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.pathol.2022.11.004_bib97","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0257976","article-title":"Prevalence of HER2 overexpression and amplification in cervical cancer: a systematic review and meta-analysis","volume":"16","author":"Itkin","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.pathol.2022.11.004_bib98","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0184123","article-title":"Prognostic significance of the co-expression of EGFR and HER2 in adenocarcinoma of the uterine cervix","volume":"12","author":"Ueda","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.pathol.2022.11.004_bib99","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1097\/PAS.0000000000001090","article-title":"Diagnostic algorithmic proposal based on comprehensive immunohistochemical evaluation of 297 invasive endocervical adenocarcinomas","volume":"42","author":"Stolnicu","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.pathol.2022.11.004_bib100","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s00795-018-0202-2","article-title":"Mucinous adenocarcinoma, gastric type of the uterine cervix: clinical features and HER2 amplification","volume":"52","author":"Nakamura","year":"2019","journal-title":"Med Mol Morphol"},{"key":"10.1016\/j.pathol.2022.11.004_bib101","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nature21386","article-title":"Integrated genomic and molecular characterization of cervical cancer","volume":"543","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.pathol.2022.11.004_bib102","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ygyno.2017.12.023","article-title":"ERBB2 mutation: a promising target in non-squamous cervical cancer","volume":"148","author":"Xiang","year":"2018","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.pathol.2022.11.004_bib103","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s10549-017-4533-9","article-title":"Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer","volume":"167","author":"Rimawi","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.pathol.2022.11.004_bib104","doi-asserted-by":"crossref","first-page":"22730","DOI":"10.1073\/pnas.1911385116","article-title":"Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy","volume":"116","author":"Zammataro","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.pathol.2022.11.004_bib105","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1038\/s41379-020-00726-1","article-title":"Massively parallel sequencing analysis of 68 gastric-type cervical adenocarcinomas reveals mutations in cell cycle-related genes and potentially targetable mutations","volume":"34","author":"Selenica","year":"2021","journal-title":"Mod Pathol"},{"key":"10.1016\/j.pathol.2022.11.004_bib106","article-title":"HER2-positive metastatic cervical cancer responsive to first and second-line treatment: a case report","volume":"31","author":"Fortman","year":"2020","journal-title":"Gynecol Oncol Rep"},{"key":"10.1016\/j.pathol.2022.11.004_bib107","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ygyno.2020.07.025","article-title":"Neratinib in patients with HER2-mutant, metastatic cervical cancer: findings from the phase 2 SUMMIT basket trial","volume":"159","author":"Oaknin","year":"2020","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.pathol.2022.11.004_bib108","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1097\/PGP.0000000000000755","article-title":"The role of predictive biomarkers in endocervical adenocarcinoma: recommendations from the International Society of Gynecological Pathologists","volume":"40","author":"Bosse","year":"2021","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.pathol.2022.11.004_bib109","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1158\/1078-0432.CCR-20-3205","article-title":"Unbiased detection of driver mutations in extramammary Paget disease","volume":"27","author":"Ishida","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pathol.2022.11.004_bib110","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ygyno.2004.07.043","article-title":"HER-2\/neu expression in Paget disease of the vulva and the female breast","volume":"95","author":"Brummer","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.pathol.2022.11.004_bib111","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1136\/jcp.2010.077446","article-title":"HER-2\/NEU overexpression in vulvar Paget disease: the Yale experience","volume":"63","author":"Richter","year":"2010","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1016\/j.pathol.2022.11.004_bib112","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1002\/cam4.2820","article-title":"Comparison of the biomarkers for targeted therapies in primary extra-mammary and mammary Paget\u2019s disease","volume":"9","author":"Gatalica","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.pathol.2022.11.004_bib113","doi-asserted-by":"crossref","first-page":"151","DOI":"10.5582\/bst.2011.v5.4.151","article-title":"The expression of HER-2 in extramammary Paget\u2019s disease","volume":"5","author":"Masuguchi","year":"2011","journal-title":"Biosci Trends"},{"key":"10.1016\/j.pathol.2022.11.004_bib114","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1111\/bjd.12249","article-title":"Human epidermal growth factor receptor 2 protein overexpression and gene amplification in extramammary Paget disease: HER2 in extramammary Paget disease","volume":"168","author":"Tanaka","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.pathol.2022.11.004_bib115","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1136\/ijgc-2020-001771","article-title":"Human epidermal growth factor receptor-2 (HER2) is a potential therapeutic target in extramammary Paget\u2019s disease of the vulva","volume":"30","author":"Bartoletti","year":"2020","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.pathol.2022.11.004_bib116","doi-asserted-by":"crossref","first-page":"763","DOI":"10.3892\/mco.2017.1422","article-title":"Successful and long-term response to trastuzumab plus paclitaxel combination therapy in human epidermal growth factor receptor 2-positive extramammary Paget\u2019s disease: a case report and review of the literature","volume":"7","author":"Ichiyama","year":"2017","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.pathol.2022.11.004_bib117","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1159\/000333002","article-title":"A\u00a0case of metastatic extramammary Paget\u2019s disease responding to trastuzumab plus paclitaxel combination therapy","volume":"3","author":"Hanawa","year":"2011","journal-title":"Case Rep Dermatol"},{"key":"10.1016\/j.pathol.2022.11.004_bib118","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.3390\/curroncol28040260","article-title":"Extramammary Paget\u2019s disease: diagnosis, pathogenesis, and treatment with focus on recent developments","volume":"28","author":"Ishizuki","year":"2021","journal-title":"Curr Oncol"},{"key":"10.1016\/j.pathol.2022.11.004_bib119","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/ijgo.13829","article-title":"Immunohistochemical expression of ErbB\/HER family proteins in patients with vulvar cancer","volume":"157","author":"Baiocchi","year":"2022","journal-title":"Intl J Gynecol Obstet"},{"key":"10.1016\/j.pathol.2022.11.004_bib120","doi-asserted-by":"crossref","first-page":"6373","DOI":"10.3390\/cancers13246373","article-title":"The Vulvar Immunohistochemical Panel (VIP) project: molecular profiles of vulvar squamous cell carcinoma","volume":"13","author":"Garganese","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.pathol.2022.11.004_bib121","doi-asserted-by":"crossref","DOI":"10.1101\/mcs.a002170","article-title":"Detection and genomic characterization of a mammary-like adenocarcinoma","volume":"3","author":"Grewal","year":"2017","journal-title":"Cold Spring Harb Mol Case Stud"},{"key":"10.1016\/j.pathol.2022.11.004_bib122","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/ccr3.3475","article-title":"Primary invasive lobular carcinoma arising in mammary-like glands of the vulva managed with neoadjuvant trastuzumab-based chemotherapy, excision, and sentinel lymph node biopsy","volume":"9","author":"Niakan","year":"2021","journal-title":"Clin Case Rep"},{"key":"10.1016\/j.pathol.2022.11.004_bib123","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(21)00521-0","article-title":"A\u00a0growing vulvar mass in a post-menopausal woman","volume":"22","author":"Xie","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.pathol.2022.11.004_bib124","first-page":"62","article-title":"HER2 testing in gastric\/gastroesophageal junction adenocarcinomas: unique features of a familiar test","volume":"4","author":"Ross","year":"2011","journal-title":"Gastrointest Cancer Res"},{"key":"10.1016\/j.pathol.2022.11.004_bib125","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.ccell.2018.09.010","article-title":"Actionable activating oncogenic ERBB2\/HER2 transmembrane and juxtamembrane domain mutations","volume":"34","author":"Pahuja","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pathol.2022.11.004_bib126","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1158\/2159-8290.CD-19-1014","article-title":"Targeting HER2 with trastuzumab deruxtecan: a dose-expansion, Phase I study in multiple advanced solid tumors","volume":"10","author":"Tsurutani","year":"2020","journal-title":"Cancer Discov"}],"container-title":["Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302522003130?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302522003130?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T16:29:13Z","timestamp":1758472153000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031302522003130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":126,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S0031302522003130"],"URL":"https:\/\/doi.org\/10.1016\/j.pathol.2022.11.004","relation":{},"ISSN":["0031-3025"],"issn-type":[{"value":"0031-3025","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of HER2 as a therapeutic biomarker in gynaecological malignancy: potential for use beyond uterine serous carcinoma","name":"articletitle","label":"Article Title"},{"value":"Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pathol.2022.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}